To validate selected putative biomarkers, RT-qPCR was performed. Total RNA, including the miRNA fraction, was isolated from blood serum samples using the
miRNeasy Serum/Plasma Kit (Qiagen Benelux, Venlo, The Netherlands), according to manufacturer’s instructions. The concentration of the RNA was determined at 260/280 nm using the
NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). For the evaluation of miRNA expression, 100 ng of total RNA was used to generate cDNA for hsa-miR-409-5p, hsa-miR-494-5p, and hsa-miR-214-3p, with reference gene hsa-miR-26b-3p (Thermofisher Scientific, Wilmington, DE, USA) using the
TaqMan MicroRNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s instructions. Determination of miRNA expression was evaluated by the
TaqMan micro-RNA assay (Applied Biosystems, Foster City, CA, USA) and run on a
Roche Lightcycler 480 thermocycler (Roche Applied Science, Basel, Switzerland) in triplicates.
Quantification of miRNA expression was performed using LinRegPCR software (2020.2.0.1, Heart Failure Research Center, AMC, Amsterdam, The Netherlands) [52 (
link)], as previously described [53 (
link)]. miRNA C
T values were normalized using the mean expression of reference gene hsa-miR-26b-3p, and relative expression was determined.
Scheper M., Romagnolo A., Besharat Z.M., Iyer A.M., Moavero R., Hertzberg C., Weschke B., Riney K., Feucht M., Scholl T., Petrak B., Maulisova A., Nabbout R., Jansen A.C., Jansen F.E., Lagae L., Urbanska M., Ferretti E., Tempes A., Blazejczyk M., Jaworski J., Kwiatkowski D.J., Jozwiak S., Kotulska K., Sadowski K., Borkowska J., Curatolo P., Mills J.D, & Aronica E. (2022). miRNAs and isomiRs: Serum-Based Biomarkers for the Development of Intellectual Disability and Autism Spectrum Disorder in Tuberous Sclerosis Complex. Biomedicines, 10(8), 1838.